CENTENNIAL, Colo., Dec. 7, 2010 /PRNewswire/ -- LABS Inc., the premier transplant reference and consultative laboratory in the country, today announced that Kevin M. Smith, Chief Operating Officer of the Colorado Institute for Drug, Device and Diagnostic Development (CID4), has joined the company's Board of Directors. Smith brings a wealth of experience running businesses in the biosciences industries.
In addition to his current role as COO of CID4, Smith was a member of the group that developed the original business plan and state grant proposal for the organization. He also sits on the boards of Sophono, Inc.; PeptiVir, Inc., and participates on the Centura Audit and Corporate Responsibility Management Committee.
Prior to CID4, Smith was Managing Director of Act Three Consulting, LLC, which provided consulting services to management teams and their advisors during times of dramatic change. Before founding Act Three, Smith spent nine years as President of Gambro, Inc., the US holding company for the publicly-traded, Swedish-based Gambro Group. The US operations of Gambro included the manufacture and distribution of cardiovascular, blood separation and renal dialysis products and the operation of US and international kidney dialysis centers. Before joining Gambro, Smith was an audit partner in the Denver and New York offices of Ernst & Young, where he specialized in entrepreneurial services and led the formation of E&Y's Denver Life Sciences Practice.
"We are honored to have Kevin join our Board of Directors at this critical time in LABS Inc.'s growth," said Elizabeth Hearty, Chief Executive Officer of LABS Inc. "His personal connection to the transplant community and his experience driving strategic growth initiatives for bioscience companies will be a valuable addition to our already accomplished Board."
"I welcome the chance to work with the LABS Inc. team to forward its mission and capitalize on opportunities to further the success of the organization," said Smith.
LABS Inc. has been serving the transplant community for nearly 30 years in the areas of infectious disease, immunogenetics and microbiology, bringing unparalleled consultative and regulatory expertise to its customers. In 2009, LABS Inc. brought its expertise to blood collection programs nationwide and now offers a complete testing menu to its blood services clients. LABS Inc.'s proven ability to manage partnerships and transport samples effectively and efficiently with timely result reporting provides the blood services community with an alternative resource for all testing needs.
About LABS Inc.
LABS Inc. is a premier transplant medicine reference laboratory bringing unparalleled consultative expertise and industry knowledge to its clients. Testing is focused on donor eligibility determination and final product safety; infectious disease testing, microbiology, histocompatibilty and environmental monitoring. LABS Inc. is committed to respectfully fulfilling the wishes of donors by ensuring the gift is able to generate positive patient outcomes. LABS Inc. employs over 100 people. The company is located in Centennial, CO with satellite facilities in St. Louis, MO and Philadelphia, PA.
SOURCE LABS Inc.